Catamaran's (CTRX) shares rose 8% to 57.03 after the pharmacy benefits manager beat Q2 profit estimates and said it would use cash on hand and financing to buy privately held Restat for $409.5 mil, expanding its client base. The companies expect to close the transaction in Q4. Catamaran's Q2 EPS climbed 76% to 49 cents vs. analysts' forecast of 44 cents. Sales rose to $3.33 bil from $1.7 bil a year ago, below views for $3.47 bil.